Register today for a LIVE national broadcast on New Treatment Options for Rare Diseases in the Soft Tissue for March 5th and 6th!

Latest from Carolina Healthcare

The foremost choice in the treatment of patients with newly diagnosed multiple myeloma is determining whether a patient is eligible for transplant, as that choice will set the stage for all future decisions.
Saad Z. Usmani, MD, FACP, discusses the need for immediate treatment intervention in patients with relapsed/refractory multiple myeloma.
Saad Z. Usmani, MD, expands on some of the key principles to inform the treatment of patients with relapsed/refractory multiple myeloma.  
Barry Paul, MD, discusses some of the newer data to emerge regarding relapsed/refractory multiple myeloma. 
Barry A. Paul, MD, discusses the role of carfilzomib in the treatment of patients with relapsed/refractory multiple myeloma.
Shebli Atrash, MD, discusses investigational combinations with venetoclax (Venclexta) in relapsed/refractory multiple myeloma.
Shebli Atrash, MD, discusses some of the latest intriguing research in relapsed/refractory multiple myeloma.
Peter Voorhees, MD, provides an overview of the many developments made with CAR T-cell therapy in multiple myeloma, as well as the exciting research being done with bispecific antibodies
Publication Bottom Border
Border Publication
x